ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 815,92
-1,49%
DAX
17 932,17
-1,10%
Brent Oil
85,93
-1,55%
Bitcoin
60 137,89
-5,80%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Moleculin Biotech Inc (MBRX)

  7. Moleculin Biotech Inc (MBRX) Actualités

MBRX Moleculin Biotech Inc

5,02
0,01 (0,20%)
Après les heures de négociation
Dernière mise à jour : 22:30:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Moleculin Biotech Inc MBRX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,01 0,20% 5,02 22:30:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,00 4,79 5,2466 5,02 5,01
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/4/202414:30PRNUSEuropean Medicines Agency (EMA) Grants Orphan Drug..
10/4/202414:30PRNUSMoleculin Announces Presentation of Positive Data..
28/3/202415:45PRNUSMoleculin to Present at the MedInvest Biotech & Pharma..
27/3/202414:25PRNUSMoleculin to Participate in the Virtual Investor Lunch..
27/3/202414:05PRNUSMoleculin Announces U.S. Patent Issue Notification for..
25/3/202412:30PRNUSMoleculin Announces Positive Interim Data in Annamycin..
22/3/202421:05PRNUSMoleculin Reports Full Year 2023 Financial Results
20/3/202412:30PRNUSMoleculin to Report Full Year 2023 Financial Results on..
20/3/202412:15IHMARKETNEWSJPMorgan boosts dividends, Chipotle unveils 50:1 stock..
19/3/202421:30PRNUSMoleculin Announces Reverse Stock Split
12/3/202414:05PRNUSMoleculin to Present at the 36th Annual ROTH Conference
29/2/202414:30EDGAR2Form 8-K - Current report
22/2/202415:30EDGAR2Form 8-K - Current report
16/2/202423:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/2/202415:15EDGAR2Form 8-K - Current report
14/2/202422:36EDGAR2Form 8-K - Current report
14/2/202422:33EDGAR2Form 8-K - Current report
13/2/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02/2/202423:05EDGAR2Form S-1 - General form for registration of securities under..
24/1/202414:50EDGAR2Form 8-K - Current report
24/1/202414:50PRNUSMoleculin Announces 2023 Year-End Annamycin Clinical Trials..
16/1/202423:00EDGAR2Form DEF 14A - Other definitive proxy statements
05/1/202423:15EDGAR2Form PRE 14A - Other preliminary proxy statements
05/1/202423:14EDGAR2Form 8-K - Current report
27/12/202313:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202323:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21/12/202323:17EDGAR2Form 8-K - Current report
21/12/202303:16PRNUSMoleculin Announces Pricing of $4.5 Million Registered..
18/12/202314:55EDGAR2Form 8-K - Current report
11/12/202314:55EDGAR2Form 8-K - Current report
11/12/202314:50EDGAR2Form 8-K - Current report
11/12/202314:50PRNUSMoleculin Presents Positive Interim Data from Phase 1B/2..
20/11/202315:15EDGAR2Form 8-K - Current report
13/11/202314:30EDGAR2Form 8-K - Current report
13/11/202314:05EDGAR2Form 8-K - Current report
13/11/202314:05PRNUSMoleculin Announces Positive Interim Data in Annamycin..
13/11/202314:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202314:00EDGAR2Form 8-K - Current report
13/11/202314:00PRNUSMoleculin Reports Third Quarter 2023 Financial Results
07/11/202314:45EDGAR2Form 8-K - Current report
07/11/202314:45PRNUSMoleculin to Report Third Quarter Financial Results on..
06/11/202314:35EDGAR2Form 8-K - Current report
06/11/202314:35PRNUSMoleculin Presents Positive Preliminary Efficacy Findings..
03/11/202321:30EDGAR2Form 8-K - Current report
17/10/202315:00EDGAR2Form 8-K - Current report
11/10/202315:05PRNUSMoleculin to Participate in the Virtual Investor Ask the CEO..
06/10/202323:15EDGAR2Form 8-K - Current report
02/10/202314:40EDGAR2Form 8-K - Current report
02/10/202314:40PRNUSMoleculin Doses First Subjects in Phase 2 Portion of..
21/9/202314:50EDGAR2Form 8-K - Current report

Dernières Valeurs Consultées

NASDAQ
MBRX
Moleculin Biotech
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés